Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | CFO AND TREASURER | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,876 |
Ending reported balance
After 2026-06-22 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 8,750 · Balance 27,626 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Row 2 · 2026-06-22 · Sale · Disposed 164 · Balance 27,462 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-06-22 · Sale · Disposed 865 · Balance 26,597 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-06-22 · Sale · Disposed 1,091 · Balance 25,506 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-06-22 · Sale · Disposed 840 · Balance 24,666 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-06-22 · Sale · Disposed 2,266 · Balance 22,400 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-06-22 · Sale · Disposed 1,994 · Balance 20,406 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-06-22 · Sale · Disposed 280 · Balance 20,126 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-06-22 · Sale · Disposed 1,250 · Balance 18,876 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-22 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 21:26 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 154 | $544.37 | $83,832.83 |
DisclosureSEC source: 0001636178-26-000026 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,676 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $543.76 to $544.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:26 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 46 | $542.94 | $24,975.12 |
DisclosureSEC source: 0001636178-26-000026 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,830 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $542.02 to $543.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 21:26 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $117.76 | $1,177,600.00 |
DisclosureSEC source: 0001636178-26-000026 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 80 | $551.76 | $44,140.40 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $551.74 to $551.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 610 | $551.28 | $336,282.39 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,956 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $550.63 to $551.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,285 | $550.09 | $706,870.40 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,566 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $549.59 to $550.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 425 | $549.38 | $233,487.31 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,851 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $548.59 to $549.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,158 | $547.91 | $1,182,392.15 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,276 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $547.52 to $548.485. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,888 | $547.03 | $1,032,791.13 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,434 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $546.51 to $547.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,989 | $546.13 | $1,086,260.33 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,322 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $545.47 to $546.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,565 | $544.93 | $852,820.77 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,311 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $544.41 to $545.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 22:06 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $117.76 | $1,177,600.00 |
DisclosureSEC source: 0001636178-26-000025 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · derivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $550.48 | $66,057.20 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $550.39 to $550.52. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,298 | $549.06 | $712,678.06 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,996 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $548.55 to $549.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,749 | $548.04 | $1,506,554.81 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,294 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $547.52 to $548.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,033 | $547.00 | $565,054.62 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,043 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $546.52 to $547.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,129 | $545.89 | $616,308.12 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,076 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $545.52 to $546.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,545 | $544.94 | $841,938.79 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,205 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $544.51 to $545.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,086 | $544.11 | $590,905.52 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,750 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $543.51 to $544.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 440 | $542.78 | $238,821.84 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,836 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $542.40 to $543.29. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 480 | $541.14 | $259,748.78 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,276 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $540.76 to $541.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $539.64 | $64,756.72 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,756 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $539.29 to $540.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $117.76 | $1,177,600.00 |
DisclosureSEC source: 0001636178-26-000024 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $554.47 | $221,788.40 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $553.97 to $554.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 280 | $552.92 | $154,816.40 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,276 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $552.76 to $553.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $550.81 | $110,162.00 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,556 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,015 | $550.20 | $558,448.43 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,756 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $549.78 to $550.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,185 | $549.30 | $650,917.18 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,771 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $548.78 to $549.775. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,606 | $548.26 | $880,511.82 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,956 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $547.76 to $548.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,354 | $547.11 | $740,789.11 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,562 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $546.75 to $547.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,520 | $546.23 | $1,376,487.76 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,916 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $545.75 to $546.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,440 | $544.96 | $784,742.26 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,436 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $544.67 to $545.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $117.76 | $1,177,600.00 |
DisclosureSEC source: 0001636178-26-000023 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · derivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 228 | $571.48 | $130,297.69 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $571.06 to $571.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 332 | $570.50 | $189,404.51 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,104 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $570.01 to $570.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 844 | $568.90 | $480,152.28 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,436 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $568.55 to $569.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,605 | $567.91 | $911,502.45 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,280 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $567.46 to $568.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 934 | $566.87 | $529,453.12 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,885 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $566.46 to $567.44. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 893 | $566.00 | $505,434.07 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,819 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $565.42 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,208 | $564.82 | $682,303.16 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,712 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $564.40 to $565.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,675 | $563.87 | $944,489.45 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,920 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $563.39 to $564.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,961 | $562.77 | $1,103,587.26 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,595 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $562.38 to $563.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 320 | $561.48 | $179,674.34 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,556 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $561.09 to $562.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:37 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $117.76 | $1,177,600.00 |
DisclosureSEC source: 0001636178-26-000022 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001636178-26-000021 · primarydocument.xml · derivative · entry 17 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 760 | $578.12 | $439,372.19 |
DisclosureSEC source: 0001636178-26-000021 · primarydocument.xml · nonDerivative · entry 16 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F16 · price: This transaction was executed in multiple trades at prices ranging from $577.84 to $578.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.